Crinetics Pharmaceuticals, Inc.
CRNX
$36.05
-$1.84-4.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 640.71% | 47.74% | 0.51% | -61.50% | -74.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 640.71% | 47.74% | 0.51% | -61.50% | -74.11% |
| Cost of Revenue | 37.57% | 42.97% | 41.20% | 17.89% | 14.70% |
| Gross Profit | -34.31% | -42.95% | -41.57% | -18.75% | -16.87% |
| SG&A Expenses | 91.84% | 87.07% | 78.25% | 71.48% | 71.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.30% | 55.74% | 51.95% | 50.92% | 49.98% |
| Operating Income | -52.50% | -55.77% | -52.21% | -51.81% | -52.22% |
| Income Before Tax | -55.87% | -52.24% | -43.05% | -39.41% | -39.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.93% | -52.24% | -43.05% | -39.41% | -39.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.93% | -52.24% | -43.05% | -39.41% | -39.10% |
| EBIT | -52.50% | -55.77% | -52.21% | -51.81% | -52.22% |
| EBITDA | -52.61% | -55.71% | -51.93% | -51.29% | -51.72% |
| EPS Basic | -33.52% | -21.96% | -9.10% | -1.20% | -0.12% |
| Normalized Basic EPS | -33.48% | -21.97% | -9.09% | -1.20% | -0.11% |
| EPS Diluted | -33.52% | -21.96% | -9.10% | -1.20% | -0.12% |
| Normalized Diluted EPS | -33.48% | -21.97% | -9.09% | -1.20% | -0.11% |
| Average Basic Shares Outstanding | 16.51% | 24.81% | 30.24% | 37.19% | 39.09% |
| Average Diluted Shares Outstanding | 16.51% | 24.81% | 30.24% | 37.19% | 39.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |